Search results
Results from the WOW.Com Content Network
Those with a bulbar onset have a worse prognosis than limb-onset ALS; a population-based study found that bulbar-onset ALS patients had a median survival of 2.0 years and a 10-year survival rate of 3%, while limb-onset ALS patients had a median survival of 2.6 years and a 10-year survival rate of 13%. [51]
From Wikipedia, the free encyclopedia. Redirect page
Articles relating to amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig's disease. It is a specific disease which causes the death of neurons controlling voluntary muscles. ALS is characterized by stiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size.
Familial ALS is the most studied; however, a new technique that was recently introduced is the use of induced pluripotent stem cells (iPSC). [2] In this study the researcher can isolate skin fibroblast from a patient with familial or sporadic ALS and reprogram them into motor neuron to study ALS. [ 2 ]
The ALS Association has partnerships with Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, [3] ALS Finding a Cure, and the Muscular Dystrophy Association. [4] Additionally, the organization is a research partner for Answer ALS (started by Steve Gleason), Target ALS (founded by Dan Doctoroff), [5] and ALS ONE.
Associated with 3-5% of ALS cases; considered an ALS risk gene rather than a causative gene as of 2018. [1] ALS25: 617921: KIF5A: 12q13.3 autosomal dominant 2018 FTD-ALS1: 105550: C9orf72: 9p21.2 autosomal dominant 2011 The gene most commonly associated with ALS, C9orf72 accounts for 40% of fALS cases and 7% of sALS cases. [2] FTD-ALS2: 615911 ...
Astrophysicist Stephen Hawking, whose ALS was diagnosed in 1963, had the disease for 55 years, the longest recorded time one had the disease. He died at the age of 76 in 2018. The 11th century monk Hermann of Reichenau had a lifelong disease that is strongly believed to have been ALS. This would make him one of the earliest known patients of ...
The institute has raised and spent more than $100 million on research into effective treatments for ALS and practices open-source science. [19] After the discovery that the multiple sclerosis drug Gilenya might also be a treatment for ALS, the Institute enrolled 30 people in a Phase 2A clinical trial the drug in 2013, though it did not progress further.